Kinoxis Therapeutics is a biotechnology company based in Melbourne, Australia, focused on the development of therapies for substance use disorders and other central nervous system conditions. Their primary product, KNX100, is a potential treatment for substance abuse, including opioids and alcohol, as well as for conditions such as stress, anxiety, and depression.

The team at Kinoxis is led by experienced professionals in the biotech industry, having held senior positions in prominent pharmaceutical and biotech companies. They are dedicated to developing and commercializing their product, KNX100, and have successfully secured substantial funding to support their research and development initiatives. Their approach combines a deep understanding of the scientific aspects of their work with a commitment to delivering practical, patient-focused solutions.

Connect